Bioray Pharmaceutical Co., Ltd.

This early-stage study tests a new drug, BR111, in about 166 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and to see how the drug behaves in the body. Researchers will also watch for any anti-tumor ac…

This early-stage study tests a new drug, BRY812, in people with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the drug every three weeks…